CD274 and cancer: Although there is a lack of prospective studies on the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients with preexisting AID, most retrospective analyses show that the efficacy of PD-1/PD-L1 inhibitors in AID patients is similar to that in the general population, and most of the irAEs were mild and controllable.